DHR vs NAGE: fair value comparison
Danaher Corporation and Niagen Bioscience, Inc. · Updated 2026-09-06
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, DHR currently sits closer to the top of our discount ranking. DHR carries the stronger quality grade.
| DHR | NAGE | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $207.66 | $3.53 |
| 12-month range | $175.15–$230.40 | $3.33–$7.89 |
| Sector rank | #62 of 113 Healthcare | #63 of 113 Healthcare |
| Quality grade | B | C |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: DHR fair value analysis · NAGE fair value analysis